Copy to clipboard 
Enovis reported 3Q25 orthopedic sales of $258 million, up 10.6% compared to the third quarter of 2024. For the first nine months of the year, the company generated $818.2 million in orthopedic sales, up 10.9% compared to the prior period.
Enovis’ international sales grew nearly 12% on a constant currency basis, driven by the integration of Lima and cross-selling across products for all anatomies. Management also cited the Prima and SMR shoulder lines as well as better in-country execution.
The ARG (augmented reverse glenoid) system continues to gain traction for Enovis while still early in its release cycle. The company has additional products in its innovation pipeline to support continued growth in extremities. Enovis’ shoulder (and knee) business will get a further boost in the first half of next year with a broader release of the ARVIS platform.
“On the Recon side, particularly in shoulder, I would say that ARG continues to be a weapon for us as we think about converting customers and it allows us to drive deeper penetration in current accounts,” said Enovis CEO Damien McDonald. “We’re seeing both happen right now, and we think there’s still a nice runway in front of ARG to continue to drive momentum in our extremities platform as we go into next year and beyond.”
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $223.7 | $201.0 | $22.7 | 11.3% |
| Knees | $56.8 | $53.6 | $3.1 | 5.8% |
| Hips | $69.7 | $65.3 | $4.4 | 6.7% |
| Extremities | $97.3 | $82.1 | $15.2 | 18.5% |
| Trauma | $25.0 | $23.3 | $1.7 | 7.3% |
| Other | $9.3 | $8.9 | $0.4 | 4.8% |
| Total | $258.0 | $233.2 | $24.8 | 10.6% |
| Segment | 9mo25 | 9mo24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $709.7 | $636.1 | $73.6 | 11.6% |
| Knees | $171.6 | $157.0 | $14.6 | 9.3% |
| Hips | $229.4 | $211.6 | $17.7 | 8.4% |
| Extremities | $308.7 | $267.4 | $41.3 | 15.5% |
| Trauma | $80.2 | $75.0 | $5.2 | 6.9% |
| Other | $28.3 | $26.8 | $1.6 | 5.8% |
| Total | $818.2 | $737.8 | $80.4 | 10.9% |
Orthopedic Sales by Geography
| Region | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $129.0 | $123.0 | $6.0 | 4.8% |
| OUS | $129.0 | $110.2 | $18.8 | 17.1% |
| EMEA | $96.1 | $82.6 | $13.5 | 16.3% |
| Asia Pacific | $19.6 | $16.0 | $3.6 | 22.7% |
| Rest of World | $13.3 | $11.6 | $1.7 | 14.9% |
| Total | $258.0 | $233.2 | $24.8 | 10.6% |
| Region | 9mo25 | 9mo24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $396.3 | $368.8 | $27.5 | 7.5% |
| OUS | $421.8 | $369.0 | $52.8 | 14.3% |
| EMEA | $317.2 | $272.9 | $44.3 | 16.2% |
| Asia Pacific | $61.3 | $53.5 | $7.9 | 14.7% |
| Rest of World | $43.3 | $42.6 | $0.7 | 1.6% |
| Total | $818.2 | $737.8 | $80.4 | 10.9% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $548.9 | |
| Cost of Sales | $219.9 | 40.1% |
| Selling and Admin | $263.6 | 48% |
| R&D | $29.7 | 13.5% |
| Other | $606.5 | 110.5% |
| Net Earnings | ($541.1) | (98.6%) |
Enovis reported 3Q25 orthopedic sales of $258 million, up 10.6% compared to the third quarter of 2024. For the first nine months of the year, the company generated $818.2 million in orthopedic sales, up 10.9% compared to the prior period.
Enovis' international sales grew nearly 12% on a constant currency basis, driven by the integration of...
Enovis reported 3Q25 orthopedic sales of $258 million, up 10.6% compared to the third quarter of 2024. For the first nine months of the year, the company generated $818.2 million in orthopedic sales, up 10.9% compared to the prior period.
Enovis’ international sales grew nearly 12% on a constant currency basis, driven by the integration of Lima and cross-selling across products for all anatomies. Management also cited the Prima and SMR shoulder lines as well as better in-country execution.
The ARG (augmented reverse glenoid) system continues to gain traction for Enovis while still early in its release cycle. The company has additional products in its innovation pipeline to support continued growth in extremities. Enovis’ shoulder (and knee) business will get a further boost in the first half of next year with a broader release of the ARVIS platform.
“On the Recon side, particularly in shoulder, I would say that ARG continues to be a weapon for us as we think about converting customers and it allows us to drive deeper penetration in current accounts,” said Enovis CEO Damien McDonald. “We’re seeing both happen right now, and we think there’s still a nice runway in front of ARG to continue to drive momentum in our extremities platform as we go into next year and beyond.”
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $223.7 | $201.0 | $22.7 | 11.3% |
| Knees | $56.8 | $53.6 | $3.1 | 5.8% |
| Hips | $69.7 | $65.3 | $4.4 | 6.7% |
| Extremities | $97.3 | $82.1 | $15.2 | 18.5% |
| Trauma | $25.0 | $23.3 | $1.7 | 7.3% |
| Other | $9.3 | $8.9 | $0.4 | 4.8% |
| Total | $258.0 | $233.2 | $24.8 | 10.6% |
| Segment | 9mo25 | 9mo24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $709.7 | $636.1 | $73.6 | 11.6% |
| Knees | $171.6 | $157.0 | $14.6 | 9.3% |
| Hips | $229.4 | $211.6 | $17.7 | 8.4% |
| Extremities | $308.7 | $267.4 | $41.3 | 15.5% |
| Trauma | $80.2 | $75.0 | $5.2 | 6.9% |
| Other | $28.3 | $26.8 | $1.6 | 5.8% |
| Total | $818.2 | $737.8 | $80.4 | 10.9% |
Orthopedic Sales by Geography
| Region | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $129.0 | $123.0 | $6.0 | 4.8% |
| OUS | $129.0 | $110.2 | $18.8 | 17.1% |
| EMEA | $96.1 | $82.6 | $13.5 | 16.3% |
| Asia Pacific | $19.6 | $16.0 | $3.6 | 22.7% |
| Rest of World | $13.3 | $11.6 | $1.7 | 14.9% |
| Total | $258.0 | $233.2 | $24.8 | 10.6% |
| Region | 9mo25 | 9mo24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $396.3 | $368.8 | $27.5 | 7.5% |
| OUS | $421.8 | $369.0 | $52.8 | 14.3% |
| EMEA | $317.2 | $272.9 | $44.3 | 16.2% |
| Asia Pacific | $61.3 | $53.5 | $7.9 | 14.7% |
| Rest of World | $43.3 | $42.6 | $0.7 | 1.6% |
| Total | $818.2 | $737.8 | $80.4 | 10.9% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $548.9 | |
| Cost of Sales | $219.9 | 40.1% |
| Selling and Admin | $263.6 | 48% |
| R&D | $29.7 | 13.5% |
| Other | $606.5 | 110.5% |
| Net Earnings | ($541.1) | (98.6%) |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
